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Abstract
Nitric oxide (NO) deficiency is common in pulmonary diseases, but its effect on pulmonary remodelling is still controversial. As pulmonary
parathyroid hormone-related protein (PTHrP) expression is a key regulator of pulmonary fibrosis and development, the effect of chronic NO
deficiency on the pulmonary PTHrP system and its relationship with oxidative stress was addressed. NO bioavailability in adult rats was reduced
by systemic administration of L-NAME via tap water. To clarify the role of NO synthase (NOS)-3-derived NO on pulmonary expression of PTHrP,
NOS-3-deficient mice were used. Captopril and hydralazine were used to reduce the hypertensive effect of L-NAME treatment and to interfere
with the pulmonary renin-angiotensin system (RAS). Quantitative RT-PCR and immunoblot techniques were used to characterize the expression
of key proteins involved in pulmonary remodelling. L-NAME administration significantly reduced pulmonary NO concentration and caused
oxidative stress as characterized by increased pulmonary nitrite concentration and increased expression of NOX2, p47phox and p67phox. Fur-
thermore, L-NAME induced the pulmonary expression of PTHrP and of its corresponding receptor, PTH-1R. Expression of PTHrP and PTH-1R
correlated with the expression of two well-established PTHrP downstream targets, ADRP and PPARc, suggesting an activation of the pulmonary
PTHrP system by NO deficiency. Captopril reduced the expression of PTHrP, profibrotic markers and ornithine decarboxylase, but neither that
of PTH-1R nor that of ADRP and PPARc. All transcriptional changes were confirmed in NOS-3-deficient mice. In conclusion, NOS-3-derived NO
suppresses pulmonary PTHrP and PTH-1R expression, thereby modifying pulmonary remodelling.
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Introduction
Nitric oxide (NO) is a widely expressed transmitter. In the lung, the
main source of NO is endothelial NO synthase (eNOS=NOS-3) that is
expressed in endothelial and epithelial cells [1–3]. Inhalation of low
levels of NO dilates vessels within well-ventilated regions of the lung
indicating a physiological role for NO in pulmonary perfusion control.
Inhaled NO was also found to normalize excessive elastin deposition
as found in chronic lung disease [4]. Endothelial dysfunction is asso-
ciated with an inability of cells to release NO and it is found in many
forms of pulmonary disease such as pulmonary arterial hypertension,
chronic obstructive pulmonary disease, congestive heart failure and
diabetes [5–9]. However, excessive NO release is also contradictory to
maintain a proper pulmonary function. In caveolin-1-deficient mice, a
subsequent persistent activation of eNOS leads to nitration of protein
kinase G, thereby inhibiting NO signalling pathways [10]. Furthermore,
NO decreases the expression of surfactant proteins in primary cultures
of type II pneumocytes and in experimental lung transplantation [11,
12]. As expected from these findings, NOS inhibition can restore pul-
monary function under some conditions such as in hyperoxia-induced
lung injury in newborn rats and nickel-induced acute lung injury [1,
13]. Interestingly, inhibition of eNOS was found to restore surfactant
gene expression [1] but a mechanistic link between eNOS-derived NO
deficiency and restored surfactant formation is lacking.
A central role in structural adaptation of the lung plays the expres-
sion of parathyroid hormone-related protein (PTHrP). PTHrP binds to
PTH-1 receptors (PTH-1R) and thereby it activates adenylyl cyclase
and subsequently cAMP-dependent protein kinase A. In the lung, this
leads to an increased expression of peroxisome proliferator-activated
receptor (PPAR)-c, leptin, and adipose differentiation-related protein
(ADRP), an increased uptake of triglycerides, a prerequisite for surfac-
tant formation, and finally attenuation of alveolar lipofibroblast-to-myo-
fibroblast transdifferentiation [14]. As expected from these previous
findings, elevated PTHrP in epithelial lining fluid negatively correlates
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with the severity of lung injury in humans [15]. Acute inhibition of NO
formation reduces the secretion of surfactant proteins. However, high
levels of NO reduced ATP-induced surfactant secretion of type-II alveo-
lar cells [16]. As both NO and PTHrP are related to surfactant and pul-
monary structure formation, we suggested that NO affects the lung by
interfering with PTHrP expression and PTH-1R activation.
Reduced NOS activity is common in many forms of pulmonary dis-
ease and favours oxidative stress and pulmonary fibrosis [17, 18]. The
coupling between low NO level and oxidative stress is a complex inter-
play between radical production by uncoupling of NOS and activation
of a local renin-angiotensin system (RAS) [19–21]. A RAS-dependent
activation of pulmonary transforming growth factor (TGF)-b1 expres-
sion may couple RAS activation and fibrosis with oxidative stress [21].
On the other hand, reduced levels of NO favour surfactant formation
and attenuate pulmonary fibrosis [1, 14]. Thus, it is highly unclear how
reduced NO formation will affect pulmonary structure and remodelling
and therefore it remains unclear how the NO system can be used to
improve future therapy of life-threatening lung diseases.
In this study, we used two different models of NO deficiency, Nx-
Nitro-L-arginine methyl ester (L-NAME)-treated rats and eNOS-defi-
cient mice, to study the effect of low NO formation on the activation
of the pulmonary PTHrP system, alveolar lipofibroblast-to-myofibro-
blast transdifferentiation and oxidative stress. Subsequently, inhibi-
tion of the local RAS system by an angiotensin-converting enzyme
inhibitor, captopril and administration of a direct vasodilating drug,
hydralazine, was used to separate effects linked to NO deficiency from
haemodynamic vascular stress. Collectively our data will show a con-
stitutive repressive role of eNOS-derived NO on the activation of the
pulmonary PTHrP system.
Materials and methods
Mice, rats and treatment protocols
L-NAME treatment (30 mg/kg/day in tap water) has been used before to
affect NO levels in rats [22]. Captopril (30 mg/kg/day in tap water) or
hydralazine (20 mg/kg/day in tap water) was administered as described
[22, 23]. L-NAME was administered to rats for 2 weeks before either
captopril or hydralazine were added with continuation of L-NAME treat-
ment. eNOS/ mice were purchased from Jackson Laboratory (strain
Nos3tm1Unc). They were crossed with C57BL/6J mice and genotyped by
tail biopsies with subsequent polymerase chain reaction (PCR) as
described before [23, 24]. All rats and mice underwent a weekly health
scoring [25]. To sacrifice the animals, rats and mice were anaesthetized
with isoflurane prior to cervical dislocation and the lungs were quickly
removed and stored in fluid nitrogen until analysis. The animal experi-
ments were approved by the local authorities. Cardiac tissue derived
from these animals has already been characterized [23].
Blood pressure
For determination of blood pressure, rats or mice were set in a separate
chamber and blood pressure (peak systolic blood pressure) was
determined via the tail-cuff method (TSE-system, 209000 Series) as
described before [22]. Briefly, the mean of 10 consecutive readings was
obtained for each animal at weekly intervals. Before the start of the
study, the animals were adjusted to the experimental procedure over
1 week.
Measurement of peroxynitrite
To estimate peroxynitrite formation in the kidney, we measured per-
oxynitrite marker nitrotyrosine by ELISA (components from Cayman
Chemicals, Ann Arbor, Michigan, USA) as previously described [23].
Briefly, lung tissue samples were pulverized in liquid nitrogen, soni-
cated in 49 homogenzation buffer and centrifuged. Supernatants
were then incubated overnight with an anti-nitrotyrosine rabbit IgG
and nitrotyrosine acetylcholinesterase tracer in pre-coated (mouse
anti-rabbit IgG) microplates flowed by development with Ellman’s
reagent. Protein concentration of the samples was measured by the
bicinchoninic acid assay.
Measurement of nitric oxide
Nitric oxide was determined in tissue samples by electron spin reso-
nance technique as described before in detail [26]. Briefly, diethyldithio-
carbamate dissolved in distilled water was injected separately from
FeSO4 and sodium citrate to avoid precipitation of Fe
2+(DETC)3. Five
minutes after treatment, lungs were isolated and freeze clamped.
Approximately 100 mg of tissue was placed into quartz tubes and
stored in liquid nitrogen until assayed for ESR spectra of NO-Fe2+-
(DETC)2 complex. electron spin resonance (ESR) spectra were recorded
with Bruker ECS 106 (Rheinstetten, Germany) spectrometer.
qRT-PCR
Total RNA was isolated from lungs using peqGold TriFast (peqlab;
Biotechnology GmbH, Erlangen, Germany) according to the manufac-
turer’s protocol as described before for heart tissues [22]. To
remove genomic DNA contamination, isolated RNA samples were
treated with 1 U desoxyribonuclease per microgram RNA (Invitrogen,
Karlsruhe, Germany) for 15 min. at 37°C. One microgram of total
RNA was used in a 10-ll reaction to synthesize cDNA using Super-
script RNaseH reverse transcriptase (200 U/lg RNA; Invitrogen) and
oligo dTs as primers. Real-time quantitative PCR was performed with
the Icycler IQ detection system (Bio-Rad, Munich, Germany) in com-
bination with IQ SYBR Green real-time PCR supermix (Bio-Rad). Pri-
mers used had the sequences according to Table 1. Quantification
was performed as described before [27].
Western blot
Tissue samples were incubated in lysis buffer as described before
for cardiac tissue [22]. Samples (100 lg) were loaded on a 12.5%
SDS-PAGE and blotted onto membranes as described before [22].
Blots were incubated with a monoclonal antibody directed against
PTHrP (antibody GF08; Calbiochem, Bad Soden, Germany) or PTH-1
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receptor (antibody 3D1.1; Upstate biotechnology, Eschborn, Ger-
rmany) as described before [28] and a second antibody coupled to
horse radish peroxidase. Surfactant production was quantified by
immunoblots detecting surfactant protein-C (SP-C; antibody FL-197,
sc-13979 Santa Cruz Biotechnology) and lipofibroblast-to-myofibro-
blast transdifferentiation was analysed by up-regulation of a-smooth
muscle protein (antibody clone 1A4, C6198 from Sigma-Aldrich; St.
Louis, USA).
Statistics
Data are expressed as mean  S.D. ANOVA and, if indicated, Student–
Neuman–Keuls test for post hoc analysis were used to analyse experi-
ments in which more than one group was compared. Exact P values for
ANOVA testing is given in the figure legend or a P value of <0.05 com-
pared to the respective control group is indicated by an asterisk. In
cases where only two groups were compared, this was done by
unpaired t-test or Mann–Whitney test depending on the equal distribu-
tion of the samples as determined by Levene test.
Results
Effect of L-NAME administration on pulmonary
NO formation and oxidative stress
First, we proved that L-NAME administration to rats successfully
reduces pulmonary NO levels. Therefore, NO levels were quantified by
ESR (Fig. 1A). The data show that L-NAME significantly reduced NO
formation by 90.7%. In parallel, reduced NO formation was accompa-
nied by elevated pulmonary content of nitrotyrosin indicating elevated
oxidative stress and functionally relevant modification of target pro-
teins (Fig. 1B). Moreover, L-NAME administration led to a significant
up-regulation of enzymes involved in the formation of reactive oxida-
tive species (ROS), such as NOX2, p47phox and p67phox (Fig. 2).
Finally, L-NAME administration induced systemic hypertension
(Table 2). Collectively, these data confirmed known effects of NO
deficiency and indicate the effectiveness of the protocol-NAME
dosage used here.
Table 1 List of primers used in this study
Forward Reverse
Rat
HPRT CCA GCG TCG TGA TTA GTG AT CAA GTC TTT CAG TCC TGT CC
PTHrP AGC TAC TCC GTG CCC TCC CG AGG AAG AAA CGG CGG CGC AA
PTH-1R GGC TGC ACT GCA CGC GCA A TTG CGC TTG AAG TCC AAC GC
ADRP GCC CGA GTC ACA ACC CCA CG AGA GTC GAC AGC CGC TCG GT
PPARc GCC GCA CGG ACG CAC ATT G GCC TCA CAC GAC CCG GTA CC
Elastin TGC TAC TGC TTG GTG GAG AAT G CGT GGC TGC TGC TGT CTG
Collagen-1 GCG AAC AAG GTG ACA GAG CCA GGA GAA CCA GCA GAG
TGF-b1 ATT CCT GGC GTT ACC TTG G CCT GTA TTC CGT CTC CTT GG
ODC GAA GAT GAG TCA AAC GAG CA AGT AGA TGT TTG GCC TCT GG
Mouse
HPRT CCA GCG TCG TGA TTA GCG AT CAA GTC TTT CAG TCC TGT CC
PTHrP GAG ATC CAC ACA GCC GAA AT CGT CTC CAC CTT GTT GGT TT
PTH-1R TTG CCT CCC TCA CCG TGG CT CGG CGC GCA GCA TAA ACG AC
ADRP CCC GCA ACC TGA CCC AGC AG CGC CTG CCA TCA CCC CCA AG
PPARc GCC TTG CTG TGG GGA TGT TCA GCG GGA AGG ACT TTA TGT
Elastin CTG CTG CTA AGG CTG CTA AG CCA CCA ACA CCA GGA ATG C
Collagen-1 TTC TCC TGG RAA AGA TGG TGC GGA CCA GCA TCA CCT TTA ACA
TGF-b1 GTC CTT GCC CTC TAC AAC CA GTT GGA CAA CTG CTC CAC CT
ODC GAA GAT GAG TCA AAT GAA CA AGT AGA TGT TTG GCC TCT GG
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Effect of NO deficiency on the PTHrP system
Once we have established that L-NAME administration significantly
affected pulmonary NO formation, we investigated next, whether L-
NAME administration modifies the expression of PTHrP and PTH-1R
in the lung. L-NAME significantly increased the pulmonary expression
of both proteins (Fig. 3A–D). Furthermore, pulmonary expression of
PTHrP mRNA and PTH-1R mRNA strongly correlated with the mRNA
expression of its downstream target genes ADRP and PPARc
(P = 0.017, r2 = 0.233 and P = 0.006, r2 = 0.433 respectively). Sim-
ilarly, mean expression of ADRP and PPARc were increased in L-
NAME-treated rats with elevated PTHrP and PTH-1R expression,
although the large variation suppressed P values below 0.05 (Fig. 3).
More importantly, L-NAME-induced increase of the mRNA expression
of PTHrP and of its corresponding receptor was confirmed on the
protein level (Fig. 4A–C). An activation of the PTHrP system has been
linked initially to surfactant production [14]. However, PTH-1R null
mice had no difference in the expression of surfactant proteins, such
as surfactant protein (SP)-C [29]. In line with the latter findings, we
did not find differences in the expression of SP-C (Fig. 4D,E).
As the PTHrP system attenuates an alveolar lipofibroblast-to-myo-
fibroblast transdifferentiation, an initial step of pulmonary fibrosis, we
expected that L-NAME-induced PTHrP expression will repress elastin
expression and therefore pulmonary fibrosis. However, in L-NAME-
treated rats elastin, collagen-1 and TGF-b1 were all up-regulated as
well as ornithine decarboxylase (ODC), a marker of cell growth
(Fig. 3E–H). This suggests an onset of pulmonary fibrosis and this
was confirmed on the protein level because the concentration of a-
smooth muscle actin increased (Fig. 4D,F).
Effect of captopril and hydralazine on L-NAME-
induced changes
The large variation in ADRP and PPARc expression suggests co-
regulation by further factors. L-NAME treatment is associated with
an activation of RAS and with hypertension. Therefore, participa-
tion of RAS activation and hypertension in the aforementioned
changes in PTHrP expression were investigated next. In the pres-
ence of captopril and hydralazine, blood pressure dropped
(Table 2). Captopril normalized the expression of PTHrP and
ADRP, but not that of PTH-1R and PPARc. Reducing the blood
pressure by administration of hydralazine was less effective than
inhibiting the RAS (Fig. 5A–D).
Pulmonary fibrosis, as indicated by up-regulation of elastin,
collagen-1, TGF-b1 and ODC, was attenuated by captopril but not
by hydralazine. This suggests that pulmonary fibrosis is triggered
by the activation of RAS rather than by high blood pressure
(Fig. 5E–H).
Pulmonary PTHrP expression in eNOS-deficient
mice
The aforementioned results suggest that pulmonary NO significantly
controls the expression of PTHrP and thereby also of its down-stream
targets ADRP and PPARc. As eNOS-derived NO is the main source of
pulmonary NO, we finally investigated whether the above mentioned
changes are depending on eNOS-derived NO. Pulmonary expression
of PTHrP, PTH-1R, ADRP and PPARc were all significantly elevated in
eNOS-deficient mice (Fig. 6A–D). In contrast, the pulmonary expres-
sion of fibrotic markers was less significantly affected by eNOS defi-
ciency and only small increases in elastin and ODC were found
(Fig. 6E–H).
Discussion
This study evaluates the role of NO for pulmonary expression and
activity of the PTHrP system. In the lung, PTHrP is expected to
increase surfactant production and to reduce lipofibroblast-to-myofi-
broblast transdifferentiation [14]. The main finding of this study is
that NO deficiency directly increases the pulmonary expression of
PTHrP and of PTH-1R. Of note, this effect was similarly found in L-
NAME-treated rats and eNOS-deficient mice. Therefore, the data of
this study identify eNOS-derived NO as an endogenous inhibitor of
the pulmonary PTHrP system. Furthermore, the data of this study
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show that NO represses the pulmonary expression of ADRP and
PPARc. Both proteins are regulated in a PTHrP-dependent way. In
vitro findings suggested that high NO levels suppress surfactant
secretion and vice versa [16]. This process depends on the activation
of the PTHrP system. Here, we observed the opposite effect and
therefore forced the view that NO suppresses surfactant formation
but lowering NO levels increases the PTHrP pathway. miR33 has been
reported to depress PTHrP expression and may be a candidate that
triggers this effects [29]. A link between NO/cGMP and miR33,
however, is still missing. A direct coupling of increased expression of
PTHrP and its down-stream targets PPARc and ADRP to surfactant
formation would require an increased expression of SP-C, but this
was not found. In agreement with these findings, studies with PTH-
1R null mice have already shown that PTHrP may not be linked to
lung development as receptor deficiency does not affect major periph-
eral proteins of the lung [30].
A dysfunctional pulmonary NO system has been implicated in
many forms of lung disease. This might be expected because
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Table 2 Effect of L-NAME on blood pressure
t = 0 t = 6 t = 8
Control 119  8 121  11 126  16 n = 9–10
L-NAME 120  15 150  15* 157  22 n = 8–10
L-NAME+Cap 117  11 163  18* 139  10# n = 10
L-NAME+Hydra 126  6 152  13* 133  12# n = 10
Data are mean  S.D. of systolic blood pressures in mmHg. *, P < 0.05 vs. t = 0; #, P < 0.05 vs. t = 6. Time-points are t = 0 (start of the L-
NAME treatment), t = 6 (6 weeks after L-NAME administration), and t = 8 (8 weeks after administration of L-NAME with 2 week treatment with
captopril and hydralazine.
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pulmonary epithelial and endothelial cells express the same constitu-
tive isoform of NOS, namely eNOS. Interestingly, while inhaled NO
and stimulation of downstream targets of NO, such as soluble guany-
lyl cyclase activators, suppress some forms of lung disease and inhi-
bit pulmonary fibrosis, blockade of NO formation was found to be
beneficial in other conditions [31]. Thus, the role of NO in adaptation
of pulmonary structure and function under stress conditions seems
to be very complex in nature. Our study confirmed earlier reports
about an effect of L-NAME on pulmonary fibrosis. In NO-deficient
mice and L-NAME-treated rats, pulmonary expressions of fibrotic
markers were collectively up-regulated under hypobaric hypoxia [17,
32]. The expression of elastin and collagen-1 were no longer
increased when L-NAME was administered in the presence of capto-
pril. In the presence of captopril, the level of TGF-b1 expression was
at least lower than that induced by L-NAME alone. In summary, this
part of the study suggests that L-NAME causes pulmonary fibrosis
via an activation of RAS. The lung has the highest angiotensin-con-
verting enzyme (ACE) activity compared to aorta, heart or kidney.
However, in contrast to the aforementioned tissues, L-NAME does
not further increase its already high activity [19]. Therefore, we sug-
gest that activation of RAS upstream of ACE triggers captopril-sensi-
tive effects of L-NAME on pulmonary remodelling. In line with these
assumptions, transgenic (mRen2)27 rats display increased expres-
sion of components of NOX and a similar increase was obtained here
in the tissue samples of L-NAME-treated rats [21]. The conclusion
that RAS rather than haemodynamic load causes the observed pul-
monary fibrosis is supported by our finding that hydralazine did not
cause a similar effect as captopril although it had a clear vasodilating
effect.
In principle, RAS-dependent activation of TGF-b may also
directly increase the expression of PTHrP in the lung. TGF-b1
induces the wnt signalling in osteolytic breast cancer cells and up-
regulates PTHrP [33]. However, it is unlikely that in the absence of
NO, the wnt pathway affects pulmonary expression of PTHrP. First,
in eNOS-deficient mice, PTHrP expression is strongly increased in
the absence of increased expression of TGF-b1. Second, in rats
captopril attenuated the expression of TGF-b1 but neither that of
PTH-1R nor that of PPARc. Furthermore, nicotine induces the wnt
pathway, but decreases the expression of PTHrP and PPARc [34].
Therefore, the role of the wnt pathway in pulmonary expression of
PTHrP has to be established in the future. Alternatively, activation
of the Notch pathway has been linked to epithelial-mesenchymal
transition. However, although in vitro studies with breast cancer
cells suggest a Notch-dependent co-regulation of PTHrP pathways
and epithelial-mesenchymal transition [33], our own experiments
in vivo with NO deficiency suggest a different regulation of these
pathways. This makes it unlikely that Notch activation plays a rele-
vant role.
Control L-NAME
SP-C
α-SM-Actin
GAPDH
D
0
50
100
150
200
Control L-NAME
E
SP
-C
 P
ro
te
in
 
(%
 o
fC
on
tr
ol
)
F
0
50
100
150
200
Control L-NAME
α-
sm
-a
ct
in
(%
 o
fC
on
tr
ol
)
P = 0.003
P = 0.897
0
50
100
150
200
250
Control L-NAME
0
50
100
150
200
250
Control L-NAME
PT
H
-R
 P
ro
te
in
(%
 o
fC
on
tr
ol
)
P = 0.012
P = 0.049
PTH-R
Actin
Control L-NAME
PTHrP
A
B
C
PT
H
rP
Pr
ot
ei
n 
(%
 o
fC
on
tr
ol
)
Fig. 4 Effect of L-NAME administration on
the pulmonary protein expression of
PTHrP, PTH-1 receptor (PTH-R), surfac-
tant protein C (SP-C), and a-smooth mus-
cle actin. Representative immunoblot is
shown (A, D); Data are mean  S.E.M.
from n = 4–6 samples.
102 ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
01
2
3
Control Capto Hydral
PT
H
rP
m
R
N
A
(x
-fo
ld
)
*
L-NAME  L-NAME
0
1
2
3
4
5
Control Capto Hydral
PT
H
-R
 m
R
N
A
(x
-fo
ld
)
L-NAME  L-NAME
*
*
0
1
2
3
Control Capto Hydral
L-NAME  L-NAME
P = 0.012 P = 0.030
P = 0.434
A
D
R
P 
m
R
N
A
(x
-fo
ld
)
0
1
2
3
4
5
6
7
8
Control Capto Hydral
PP
A
R
γ
m
R
N
A
(x
-fo
ld
)
P = 0.083
A B
DC
L-NAME  L-NAME
0
2
4
6
8
10
12
14
16
18
Control Capto Hydral
El
as
tin
 m
R
N
A
(x
-fo
ld
)
P = 0.072
E
L-NAME  L-NAME
0
1
2
3
4
Control Capto Hydral
P = 0.042
C
ol
la
ge
n-
1 
m
R
N
A
(x
-fo
ld
)
F
*
0
1
2
3
4
5
Control Capto Hydral
TG
F-
β1
 m
R
N
A
(x
-fo
ld
)
G
P = 0.003 *
0
1
2
3
4
5
6
7
Control Capto Hydral
O
D
C
 m
R
N
A
(x
-fo
ld
)
*P = 0.003
H
L-NAME  L-NAME
L-NAME  L-NAMEL-NAME  L-NAME
Fig. 5 Effect of captopril and hydralazine
on L-NAME-induced changes in the pul-
monary mRNA expression of PTHrP, PTH-
1 receptor, and PTHrP downstream tar-
gets ADRP and PPARc and that of fibrotic
markers. Data are mean  S.D. from
n = 6 samples. Exact P values are given
*, P < 0.05 vs. control.
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
103
J. Cell. Mol. Med. Vol 21, No 1, 2017
0
2
4
6
8
10
12
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
PT
H
rP
m
R
N
A
(x
-fo
ld
) A
*P = 0.000
0
2
4
6
8
10
12
14
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–P
TH
-1
R
 m
R
N
A
(x
-fo
ld
)
P = 0.001 *
B
0
1
2
3
4
5
6
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
A
D
R
P 
m
R
N
A
(x
-fo
ld
)
C
P = 0.000
*
0
1
2
3
4
5
6
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
PP
A
R
γ
m
R
N
A
(x
-fo
ld
)
P = 0.008
*
D
0
1
2
3
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
El
as
tin
 m
R
N
A
(x
-fo
ld
) E
P = 0.016
*
0
1
2
3
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
P = 0.088
C
ol
la
ge
n-
1 
m
R
N
A
(x
-fo
ld
) F
0
1
2
3
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
TG
F–
β1
 m
R
N
A
(x
-fo
ld
)
P = 0.973
G H
0
1
2
3
eN
O
S+
/+
eN
O
S+
/–
eN
O
S–
/–
O
D
C
 m
R
N
A
(x
-fo
ld
)
P = 0.003 *
Fig. 6 Effect of eNOS deficiency on pul-
monary expression of PTHrP (A), PTH-1
receptor (B), ADRP (C), PPARc (D), elas-
tin (E); collagen-1 (F), TGF-b1 (G), and
ODC (H) in wild-type mice (+/+), heterozy-
gous mice () and eNOS knockout mice
(/). *, P < 0.05 vs. eNOS +/+ Data are
mean  S.D. from n = 9–23 mice.
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In this study we used the expression of elastin as a marker of pul-
monary fibrosis because excessive elastin deposition characterizes
chronic lung disease [4]. Furthermore, we analysed the pulmonary
expression of collagen-1 and TGF-b1 because epithelial-mesenchymal
transition is favoured by TGF-b1- and TGF-b1-dependent collagen-1
synthesis but reciprocally expressed in the presence of NO [35].
Epithelial-mesenchymal transition was further confirmed by increased
a-smooth muscle protein. Finally, we analysed the expression of pul-
monary ornithine decarboxylase (ODC) because this rate-limiting
enzyme of the polyamine metabolism is required for pulmonary tissue
growth and remodelling [36]. In our study, NO deficiency affected the
PTHrP system and the RAS-TGF-b1 cascade in a different way. There-
fore, we conclude that the pulmonary PTHrP system seems more clo-
sely linked to ADRP and PPARc rather than to inhibition of pulmonary
fibrosis. This does not mean that an activated PTHrP system does not
attenuate the alveolar transepithelial-to-myofibroblast transdifferenti-
ation, as suggested before, but in the context of NO deficiency its
main effect is on ADRP and PPARc expression rather than on fibrosis.
At the same time, an activation of RAS overrides a potential anti-fibro-
tic effect of PTHrP. From a therapeutic point of view this leads to a
dilemma: Although NO deficiency increases PTHrP expression and
thereby ADRP and PPARc expression, the same trigger favours pul-
monary fibrosis. An activation of RAS and RAS-dependent oxidative
stress may support this consequence of NO deficiency as this went
alongside with increased expression of NOX2, p47phox and p67phox.
Indeed, we found not only a significant drop in pulmonary NO, as
determined by direct measurement of NO by ESR but also an increase
in tissue nitrotyrosine, a marker of oxidative stress relative to NO.
In summary we came to the following view as indicated in Fig. 7:
NO constitutively represses pulmonary PTHrP and PTH-1R expres-
sion thereby keeping expression of ADRP and PPARc rather low. NO
deficiency and the lack of soluble guanylyl cyclase stimulation acti-
vates RAS that then triggers pulmonary fibrosis most probably by its
ROS-forming effect. At the same time, pulmonary PTHrP is induced
but not sufficient to compensate the pro-fibrotic effect of RAS
activation.
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